All In Biotech

NDA 022256 · Abbvie

Savella

Milnacipran Hydrochloride · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Sep 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jan 14, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

73

24 Phase 3, 1 recruiting

FAERS reports

6,009

2,554 serious, 156 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS Milnacipran hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), similar to some drugs used for the treatment of depression and other psychiatric disorders. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of such drugs in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are...

What it is approved for

From the label in effect Mar 19, 2026.

Milnacipran hydrochloride is indicated for the management of fibromyalgia. Milnacipran hydrochloride is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )] . • Milnacipran hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia ( 1 ). • Milnacipran hydrochloride is not approved for use in pediatric patients ( 1 ).

Mechanism: The exact mechanism of the central pain inhibitory action of milnacipran and its ability to improve the symptoms of fibromyalgia in humans are unknown. Preclinical studies have shown that milnacipran is a potent inhibitor of neuronal norepinephrine and serotonin reuptake; milnacipran inhibits norepinephrine uptake with approximately 3-fold higher potency in vitro than serotonin without directly affecting the uptake of dopamine or other neurotransmitters. Milnacipran has no significant affinity for serotonergic (5-HT1-7), α- and β-adrenergic, muscarinic (M1-5), histamine (H1-4), dopamine...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • SAVELLA · MILNACIPRAN HYDROCHLORIDE 100MG · TABLET, ORAL · Prescription · TE AB
  • SAVELLA · MILNACIPRAN HYDROCHLORIDE 25MG · TABLET, ORAL · Prescription · TE AB
  • SAVELLA · MILNACIPRAN HYDROCHLORIDE 50MG · TABLET, ORAL · Prescription · TE AB
  • SAVELLA · MILNACIPRAN HYDROCHLORIDE 12.5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Milnacipran" as an intervention, any sponsor and status, largest first.

All 73 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea699
  • pain522
  • headache489
  • drug ineffective480
  • vomiting363
  • fatigue347
  • dizziness343
  • insomnia329
  • depression301
  • hyperhidrosis288
  • off label use276
  • anxiety268

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20055
20064
20075
20087
2009493
2010789
2011586
2012389
2013342
2014304
2015414
2016612
2017375
2018347
2019248
2020251
2021160
2022176
2023139
2024141
2025132
202687

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Savella (Milnacipran HCl)

2024 spending

$59.3M

Beneficiaries

16,606

82,321 claims

Per beneficiary

$3,572

$7.96 per unit

View as table
YearSpending
2020$59,799,645
2021$59,927,908
2022$60,127,012
2023$61,126,083
2024$59,322,983

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 147 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.